Crispr Therapeutics AG (CRSP)

Crispr Therapeutics AG (CRSP) Income Statement


Crispr Therapeutics AG Income Statement

Last quarter (Q1 2023), Crispr Therapeutics AG's total revenue was $100.00M, an increase of 56079.78% from the same quarter last year. In Q1, Crispr Therapeutics AG's net income was $-53.06M. See Crispr Therapeutics AG’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 100.26M$ 436.00K$ 913.08M$ 719.00K$ 289.59M$ 3.12M
Cost of Revenue
$ 79.60M$ 110.25M----
Gross Profit
$ 20.65M$ -109.81M----
Operating Expense
$ 582.33M$ 563.35M$ 539.55M$ 355.15M$ 242.85M$ 162.07M
Operating Income
$ -561.68M$ -673.16M$ 373.53M$ -354.44M$ 46.74M$ -158.94M
Net Non Operating Interest Income Expense
-----$ 0.00
Other Income Expense
$ 9.56M$ 22.66M$ 6.00M$ 6.38M$ 20.57M$ -5.49M
Pretax Income
$ -526.64M$ -650.50M$ 379.53M$ -348.06M$ 67.31M$ -164.43M
Tax Provision
$ -2.61M$ -325.00K$ 1.87M$ 809.00K$ 448.00K$ 553.00K
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -524.02M$ -650.17M$ 377.66M$ -348.87M$ 66.86M$ -164.98M
Basic EPS
$ -6.72$ -8.36$ 4.97$ -5.29$ 1.23$ -3.44
Diluted EPS
$ -6.72$ -8.36$ 4.70$ -5.29$ 1.17$ -3.44
Basic Average Shares
$ 312.55M$ 77.75M$ 75.95M$ 65.95M$ 56.93M$ 47.96M
Diluted Average Shares
$ 312.55M$ 77.75M$ 80.39M$ 65.95M$ 56.93M$ 47.96M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 661.93M$ 673.60M$ 539.55M$ 355.15M$ 242.85M$ 162.07M
Net Income From Continuing And Discontinued Operation
$ -524.02M$ -650.17M$ 377.66M$ -348.87M$ 66.86M$ -164.98M
Normalized Income
$ -470.96M$ -650.17M$ 377.66M$ -348.87M$ 66.86M$ -164.98M
Interest Expense
-----$ 0.00
$ -548.93M$ -673.16M$ 373.53M$ -354.44M$ 46.74M$ -158.94M
$ -525.75M$ -648.99M$ 391.48M$ -345.25M$ 51.47M$ -155.42M
Currency in USD

Crispr Therapeutics AG Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis